Thanks. I saw that post from BioForGood, but this was questioned as not being true from another poster (San Diego living), Notwithstanding his post, BioForGood, also said he was not about to sell his shares at such a depressed share price. Also another poster (Bob Good) posted the following:
"Thank you @BioForGood for valuable info..
But, I am still optimistic. Why?
Three main routes to market in China: private, out-of-pocket/patient assistance schemes & public reimbursement.
Out-of-pocket/patient have typically been the first route by manufactures, and with a rising middle class, this route presents a sizeable 30% opportunity..
Via NRDL means fully or partially reimbursed at a national level in public hospitals. Historically such drugs were generics.. may be good for Vazkepa after AG in US?
More opportunity via NRDL for access has it's own drawbacks. China has made strikingly high demands, sometimes asking for discounts as high as 90% !!! But this negates having to also reduce prices in other countries which may quote China!!
So, I am still hopeful for out of packet route for $AMRN. Why? Because, even if Vazkepa captures 1% of China’s CVD market (330M) could generate > $3B.
GL Longs.
I will post the relevant link from which I collected the above info..
Bullish
BioForGood
Yesterday 8:00 PM"
So based on the above, who are we to believe... without any public confirmation all of these news seem unconfirmed so far?
Market Data 
Markets 
AI
